TRXADE HEALTH INC (MEDS)
US89846A4058 - Common Stock
MEDS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 40 industry peers in the Health Care Technology industry. Both the profitability and financial health of MEDS have multiple concerns. MEDS is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
MEDS had negative earnings in the past year.
In the past year MEDS had a positive cash flow from operations.
In the past 5 years MEDS reported 4 times negative net income.
In multiple years MEDS reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of MEDS (-32.81%) is comparable to the rest of the industry.
The Return On Equity of MEDS (-61.46%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.81% | ||
| ROE | -61.46% | ||
| ROIC | N/A |
ROA(3y)-70.56%
ROA(5y)-43.25%
ROE(3y)-208.98%
ROE(5y)-126.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of MEDS (70.91%) is better than 69.23% of its industry peers.
MEDS's Gross Margin has declined in the last couple of years.
MEDS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.91% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.08%
GM growth 5YN/A
2. Health
2.1 Basic Checks
MEDS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MEDS has more shares outstanding
Compared to 5 years ago, MEDS has more shares outstanding
The debt/assets ratio for MEDS is higher compared to a year ago.
2.2 Solvency
MEDS has an Altman-Z score of -0.99. This is a bad value and indicates that MEDS is not financially healthy and even has some risk of bankruptcy.
MEDS has a Altman-Z score of -0.99. This is comparable to the rest of the industry: MEDS outperforms 41.03% of its industry peers.
MEDS has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
MEDS's Debt to Equity ratio of 0.00 is fine compared to the rest of the industry. MEDS outperforms 71.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.99 |
ROIC/WACCN/A
WACC13.93%
2.3 Liquidity
MEDS has a Current Ratio of 0.61. This is a bad value and indicates that MEDS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of MEDS (0.61) is worse than 82.05% of its industry peers.
A Quick Ratio of 0.28 indicates that MEDS may have some problems paying its short term obligations.
MEDS has a Quick ratio of 0.28. This is amonst the worse of the industry: MEDS underperforms 87.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.61 | ||
| Quick Ratio | 0.28 |
3. Growth
3.1 Past
MEDS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -151.31%.
The Revenue for MEDS has decreased by -19.65% in the past year. This is quite bad
MEDS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.34% yearly.
EPS 1Y (TTM)-151.31%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-402.2%
Revenue 1Y (TTM)-19.65%
Revenue growth 3Y15.45%
Revenue growth 5Y31.34%
Revenue growth Q2Q-14.25%
3.2 Future
MEDS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 38.00% yearly.
The Revenue is expected to decrease by -9.78% on average over the next years.
EPS Next Y77.69%
EPS Next 2Y38%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-21.81%
Revenue Next 2Y-9.78%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MEDS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MEDS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MEDS's earnings are expected to grow with 38.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38%
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 126.78%, MEDS is a good candidate for dividend investing.
MEDS's Dividend Yield is rather good when compared to the industry average which is at 34.67. MEDS pays more dividend than 100.00% of the companies in the same industry.
MEDS's Dividend Yield is rather good when compared to the S&P500 average which is at 2.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 126.78% |
5.2 History
MEDS does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y38%
EPS Next 3YN/A
TRXADE HEALTH INC
NASDAQ:MEDS (4/30/2024, 3:30:01 PM)
5.96
-0.34 (-5.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.21M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 126.78% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.81% | ||
| ROE | -61.46% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.91% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.42
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.61 | ||
| Quick Ratio | 0.28 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-151.31%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y77.69%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-19.65%
Revenue growth 3Y15.45%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y